The New Billionaire Bet Isn’t AI — It’s Longevity Biotech
The New Billionaire Bet Isn’t AI — It’s Longevity Biotech
Publish Date: 2026-06-11 09:00:00
Source Domain: www.forbes.com
Researchers are increasingly using AI and biotechnology tools to better understand the biological mechanisms associated with aging.
getty
Silicon Valley spent the last three years obsessed with artificial intelligence.
Now some of its wealthiest investors are making another bet: rewriting biology itself.
According to an analysis by Longevity.Technology based on PitchBook data, longevity biotech companies raised approximately $3.74 billion across 49 financing events during the first quarter of 2026, up 56% from the same period a year earlier. The sector is attracting billionaire investors, pharmaceutical partners, and some of the largest funding rounds in biotechnology.
Longevity is moving beyond academic research and into drug development.
Investors are increasingly backing companies with clear paths to clinical validation, reflecting a broader shift toward therapies that can be tested, regulated, and eventually brought to market.
Why Now?
Three forces converged to make 2026 feel different from previous longevity cycles.
The first is artificial intelligence.
The same technologies transforming software are now accelerating biology. Researchers use AI to analyze genomic data, identify therapeutic targets, prioritize experiments and narrow enormous search spaces that would have previously required years of trial and error.
At NewLimit, the epigenetic reprogramming company co-founded by Coinbase co-founder Brian Armstrong, researchers say AI has fundamentally changed the pace of discovery.
“We built an AI system to prioritize the reprogramming medicines we test in the lab,” said Jacob Kimmel, Co-Founder and CEO of NewLimit. “The system allows researchers to make discoveries more than twice as fast as relying on human intuition alone.”
The second force is economic.
According to DrugPatentWatch, between 2025 and 2030, an estimated $236 billion to $300 billion in annual pharmaceutical revenue will face loss of exclusivity as patents expire on roughly 70 blockbuster drugs….
